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Objective: To validate the Danish National Patient Register’s (NPR) diagnoses of pediatric 
acquired demyelinating syndromes (ADS) including multiple sclerosis (MS).
Study design and setting: We identified ADS diagnostic groups using International Clas-
sification of Diseases (ICD) codes and reviewed medical records to validate the NPR diagnoses 
during 2008–2015.
Results: Among 409 children in the study, 184 children had a validated and final ADS 
diagnosis after reviewing medical records as follows: optic neuritis (ON; n=46), transverse 
myelitis (TM; n=16), acute disseminated encephalomyelitis (ADEM; n=50), clinically iso-
lated syndrome (CIS) including dissemination in space (CIS [DIS]) but not dissemination in 
time (n=6), neuromyelitis optica spectrum disorder (NMOsd; n=5), and MS (n=61). During 
the mean follow-up of 4.6 years, 33% of children initially diagnosed with monophasic ADS 
progressed to MS. Positive predictive value (PPV) was 0.71 (95% confidence interval [CI] 
=0.62–0.80) for ON, 0.64 (95% CI =0.43–0.82) for TM, 0.93 (95% CI =0.84–0.98) for MS, 
0.27 (95% CI =0.19–0.35) for CIS, 0.43 (95% CI =0.10–0.82) for NMOsd, and 0.15 (95% 
CI =0.10–0.20) for ADEM. Assuming complete coverage for non-MS ADS, the sensitivity 
was 0.99 (95% CI =0.93–1.00) for ON, 0.83 (95% CI =0.36–1.00) for CIS (DIS), and 0.80 
(95% CI =0.56–0.94) for TM, but only 0.58 (95% CI =0.43–0.72) for ADEM and 0.60 (95% 
CI =0.15–0.95) for NMOsd.
Conclusion: PPV was high for MS and considered acceptable for ON and TM; therefore, 
these ICD revision 10 (ICD-10) codes from the NPR are useful for epidemiological studies. 
Conversely, PPV was low for CIS and ADEM; NMOsd was inconclusive.
Keywords: pediatric MS, acquired demyelinating syndrome, ADEM, health registers, valida-
tion, ICD-10
Introduction
The Danish National Patient Register (NPR) is a nationwide register that has routinely 
collected administrative and health-related data on all hospital admissions in Denmark 
since 1977.1 Despite numerous validation studies of the NPR,2–13 the validity of the 
International Classification of Diseases revision 10 (ICD-10) codes for pediatric 
acquired demyelinating syndromes (ADS) has not been examined. The NPR may 
provide easily accessible population-based disease surveillance and facilitate epide-
miological research in pediatric ADS.
However, challenges exist unique to interpreting diagnostic ICD-10 codes for ADS:
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1. Presumed monophasic ADS (eg, optic neuritis [ON]) 
can progress to multiple sclerosis (MS) or neuromyelitis 
optica spectrum disorder (NMOsd), causing the mono-
phasic ADS to represent the onset of MS or NMOsd at a 
later point. Therefore, the true incidence of monophasic 
ADS decreases as follow-up increases if relapses of 
monophasic ADS convert the child’s diagnosis to MS or 
NMOsd; accordingly, NMOsd and MS could be underdi-
agnosed with a short follow-up due to reporting delay.14,15
2. Once a person is diagnosed with MS, a new clinical event 
with ON may be interpreted in light of MS and therefore 
be coded as a relapse of MS instead of ON.
3. Difficulty in comparing the diagnoses of MS and NMOsd 
over time is reflected by continuous revisions of the diag-
nostic criteria for MS with the inclusion of the McDonald 
criteria in 2001, facilitating the use of magnetic resonance 
imaging (MRI) to show dissemination in space and time, 
and, for NMOsd with the incorporation of aquaporin-4 
(AQ4) antibodies in 2006.16–20 However, the diagnostic 
ICD-10 codes for MS (G35) and NMOsd (G36.0) have 
not changed in line with these revisions, causing misclas-
sification of patient groups over time.
4. Discrepancy exists between the proposed consensus cri-
teria for acute disseminated encephalomyelitis (ADEM) 
and how pediatric neurologists diagnose ADEM in clini-
cal practice, particularly regarding whether encephalopa-
thy and polyfocal neurological deficits are required for 
ADEM.21,22
5. Requirements in published articles vary for disease 
progression to MS in children initially diagnosed with 
ADEM because some researchers diagnose MS after any 
relapse, whereas the criteria of the International Pediatric 
MS Study Group (IPMSSG) state that a second clinical 
event must be without encephalopathy and an MRI dem-
onstrating dissemination in space.21,23
6. Neurologists in Denmark may be more inclined to code 
a child with ON as “demyelinating disease of central 
nervous system (CNS), unspecified” (G37.9) instead of 
ON (H46) if the child also has dissemination in space 
on the MRI and cerebrospinal fluid oligoclonal band 
positivity.
Using the validation study reporting guidelines proposed 
by Benchimol et al,24 we aimed to estimate common epide-
miological outcome measures, such as the positive predictive 
value (PPV) and sensitivity of diagnostic ICD-10 codes, for 
pediatric ADS in the NPR during 2008–2015, using retro-
spective chart review as the gold standard.
Methods
The Danish NPR
The NPR was established in 1977 and contains nationwide 
information on all patients admitted to Danish hospitals. Data 
include date of admission and final diagnoses according to 
the ICD-8 (1977–1993) and ICD-10 (1994 until today).1 At 
hospital discharge, physicians code each patient by diagno-
sis with one primary diagnosis and, if relevant, one or more 
secondary diagnoses. Patients can receive more diagnoses 
at other hospital discharges or at ambulatory hospital con-
sultations. In Denmark, hospital admissions and outpatient 
visits are tax funded and free of charge. Patients are coded 
at each visit, giving chronically diseased patients multiple 
registrations.2 Private consultant physicians (eg, general 
practitioners, neurologists, and ophthalmologists) and private 
hospitals in Denmark play a minor role in the diagnostic 
procedure and always refer children with suspected demy-
elinating disease to public hospitals.
The Danish Civil Registration System
The Danish Civil Registration System was established in 
1968 as a register of residents in Denmark.13,25 In Denmark, 
every resident is provided with a unique personal identifica-
tion number that includes date of birth and sex. The personal 
identification number is used for multiple purposes in Den-
mark, allowing linkage of patients between various registers. 
Variables include date of migration and vital status.
Validation cohort
At onset, all patients were younger than 18 years and living 
in Denmark. In 2010, Denmark’s population was 5,547,683, 
with 1,196,891 (22%) younger than 18 years.26 Denmark has 
a relatively homogeneous Caucasian population.
During January 1, 2008, to December 31, 2015, we 
identified children in the NPR using non-MS ADS diagnos-
tic codes in the Danish version of ICD-10. Subsequently, 
we reviewed the children’s medical records to verify their 
diagnoses. We used the following diagnostic ICD-10 codes 
(ICD-10 in brackets): ON (H46), transverse myelitis (TM) 
(G37.3), and NMOsd (G36.0). As a specific diagnostic code 
for demyelinating events caused by supratentorial lesions 
does not exist, we defined this as “clinically isolated syn-
drome” (CIS) (G36.8, G36.9, G37.8, and G37.9). Similarly, 
we defined a diagnostic group for ADEM (G04.0, G04.8, 
and G04.9). For the latter two groups, ICD-10 codes were 
defined pre hoc with expertise from both adult and pediatric 
neurologists based on presumed standards for diagnostic 
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coding among physicians. All patients’ diagnostic ICD-10 
codes of ADS were included (Table S1).
Owing to the risk of developing a chronic demyelinat-
ing disease, children with non-MS ADS are usually referred 
to hospitals as either admissions or outpatient ambulatory 
consultations, with subsequent ICD-10 code notification 
to the NPR. Due to the structure of the Danish health care 
system with few private consultant pediatricians or pediatric 
ophthalmologists, it is unlikely that children with non-MS 
ADS are not registered with one of the aforementioned diag-
nostic codes. In Denmark, patients with ON before the age 
of 18 years are referred to a hospital for further diagnostic 
workup.
Definition of diagnoses
The term ADS refers to all acquired demyelinating diseases of 
the CNS. ADS can be divided into the following two groups: 
1) MS and 2) non-MS ADS, the latter consisting of ON, TM, 
NMOsd, ADEM, and CIS. CIS included children with ADS 
who could not be classified into one of the other categories, 
eg, hemispheric and brainstem demyelinating syndromes; in 
addition, we defined CIS including dissemination in space but 
not dissemination in time as CIS (DIS). “Dissemination in 
space” refers to ≥1 T2 MRI lesions in at least two of the four 
MS typical regions of the CNS (periventricular, juxtacortical, 
infratentorial, or spinal cord).20 “True diagnoses” were based 
on the chart review including laboratory and MRI investiga-
tions. For the chart review, MS was defined by the McDonald 
criteria at the time of diagnosis, either the 2005 revision or 
the 2010 revision.19,20 NMOsd was defined by the Winger-
chuk criteria.17 ON was based on the ophthalmologist’s final 
diagnosis. In Denmark, diagnostic workup of ON includes 
AQ4 antibody testing with enzyme-linked immunosorbent 
assay technique if the ON is bilateral, recidivating or asso-
ciated with TM. TM was defined as neurological symptoms 
from the spine verified by a spinal MRI with corresponding 
lesions and a brain MRI not fulfilling the MS McDonald 
criteria.20 A diagnosis of ADEM included an abnormal MRI 
and neurologic symptoms with a varying degree of encepha-
lopathy and neurological deficits. Progression from ADEM 
to MS was defined by IPMSSG criteria.21 As children with 
monophasic ADS (such as ON) can progress to relapsing 
ADS, we recorded whether children initially diagnosed with 
presumed monophasic ADS progressed to relapsing disease 
(NMOsd or MS) during follow-up (June 1, 2016).
MSB, who is a medical doctor and has 5 years of clini-
cal training including 1 year of pediatrics and 2 years of 
 neurology, reviewed the medical records under the supervi-
sion of a senior pediatric neurologist. MSB was not blinded 
to children’s diagnostic codes during chart review. Case notes 
were reviewed during June–August 2016.
Statistical methods
We calculated PPVs including exact confidence intervals 
(CIs) as the proportion of children in each ICD-10 diagnostic 
group who truly had the ADS of interest and, based on popula-
tion numbers in Denmark, the negative predictive values as 
the proportion of children without a diagnostic code of the 
ADS of interest who truly did not have the ADS of interest. 
Sensitivity was estimated as the proportion of children with 
the specific ICD-10 code among those who truly had the ADS 
of interest, and specificity was estimated as the proportion of 
children without the specific ICD-10 code among those who 
truly did not have the ADS of interest. Likelihood ratios were 
estimated as the probability of children having the ICD-10 
code of ADS of interest who truly had the ADS of interest 
divided by the probability of the same finding in children 
who did not truly have the ADS of interest.
We calculated the point prevalence of ADS among 
children (<18 years of age) in Denmark as the sum of the 
age-specific incidence rates times the remaining years up 
to 18 years of age by using date of onset (and not date 
of diagnosis) as onset of ADS. This is appropriate as the 
rates of migration and death among Danish children and 
adolescents are low.26
We calculated PPVs based on the inclusion of primary 
diagnoses only, one diagnostic code registration among 
primary and secondary diagnoses, and at least two code 
registrations among primary and secondary diagnoses. In 
addition to calculating the PPV in each diagnostic group 
for the specific ADS, we calculated the PPV in each group 
for any ADS. Furthermore, we calculated the proportion of 
children with presumed monophasic ADS who progressed 
to relapsing disease (MS, NMOsd or multiphasic ADEM) 
during follow-up. The statistical analyses were performed 
using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Ethics
The study was approved by the Danish Data Protection 
Agency (case number: 30-1423/03567) and the Danish 
Health Data Authority (case number: 00001716). The Danish 
Health and Medicines Authority waived the requirement to 
obtain patient informed consent to access medical records 
(case number: 3-3013-896/1).
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Results
Validation process
We included 415 children during 2008–2015 using the 
aforementioned ADS diagnostic codes (Figure 1), giving 
1,087 diagnostic ICD-10 code registrations for ADS. Medical 
records were accessed electronically; none was missing. We 
excluded four children because they were foreign residents 
and, therefore, the follow-up case notes were incomplete, and 
two children because chart review revealed that ADS onset 
was before the study period. After reviewing the medical 
records, 184 children truly had ADS, among whom 61 chil-
dren progressed to MS during follow-up. During follow-up 
of all 415 children, 13 children died and two children emi-
grated; among these 15 children, only one child was truly 
diagnosed with ADS. Among the five children with NMOsd, 
one child had ON and positive AQ4, one child had ON and 
subsequently TM but negative AQ4, and three children had 
TM and positive AQ4; two children with NMOsd were tested 
for anti-myelin oligodendrocyte glycoprotein (MOG) anti-
bodies, and one test was positive. For the remaining children 
initially diagnosed with monophasic ADS, we retrieved the 
following information regarding AQ4 and MOG antibodies 
(positive tests/total known test results): ADEM: AQ4 (1/11), 
MOG (1/2); ON: AQ4 (0/8), MOG (1/2); CIS (DIS): AQ4 
(0/0), MOG (0/0); and TM: AQ4 (0/9), MOG (1/2).
Baseline characteristics
For ADEM, the median age at onset was 5.4 years, whereas 
the median age for the other ADS was 12 years or older at 
onset. The majority of children with ADEM and TM were 
boys; for the other ADS groups, girls formed the majority 
(Table 1).
PPV of ADS
The PPV in children with at least one diagnostic code as 
either primary discharge diagnosis or secondary discharge 
184
338
409
Medical record review
(n=415)
Children registered with one of the following diseases (ICD-10 codes in
parentheses) in the Danish National Patient Register during 2008–2015:
ADEM (G04.0, G04.8, G04.9)
CIS (G36.8, G36.9, G37.8, G37.9)
NMOsd (G36.0)
TM (G37.3)
ON (H46)
Foreign residents (n=4)
Onset outside the study period (n=2)
Encephalitis
(n=71)
Other rare diseases outside the
scope (n=154)
ON
(n=78)
ON
(n=46)
TM
(n=16)
ADEM
(n=50)
CIS (DIS) 
(n=6)
NMOsd
(n=5)
MS
(n=61)
At onset
At follow-up end (June 2016)
TM
(n=20)
ADEM
(n=50)
CIS
(n=35)
MS
(n=1)
Figure 1 Flow diagram of the study population of children (<18 years) with acquired demyelinating syndromes at onset and at follow-up end.
Abbreviations: ADEM, acute disseminated encephalomyelitis; CIS, clinically isolated syndrome; CIS (DIS), CIS including dissemination in space; ICD-10, International 
Classification of Diseases revision 10; NMOsd, neuromyelitis optica spectrum disorder; ON, optic neuritis; TM, transverse myelitis.
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of the specific ADS), the PPVs increased markedly for CIS, 
TM, and NMOsd.
ADEM and ICD-10 codes
As ADEM is the commonest ADS in children, we explored 
which diagnostic ICD-10 codes pediatricians usually used in 
children with a medical record verified diagnosis of ADEM. 
Among the 50 children who truly had ADEM, 29 children 
had at least one of the aforementioned ICD-10 codes of 
ADEM; among these children, 25 children had onset before 
the age of 10 years. However, among the remaining cohort 
of children without ADEM (n=359), 168 (47%) children also 
had an ICD-10 code of ADEM. Additionally, 94 children 
without ADEM had an ICD-10 code of ADEM and the code 
registration before the age of 10 years. The commonest non-
ADEM diseases coded by physicians using our prespecified 
ADEM codes were epilepsy and other forms of encephalitis.
Progression from monophasic ADS to MS 
or NMOsd
As the distinction between monophasic and relapsing diseases 
is important, we calculated the cumulative proportion of MS 
and NMOsd during follow-up in children initially diagnosed 
with presumed monophasic ADS (Table 3). During follow-up 
of 4.6 years (range =0.3–9.4 years), 33% of children initially 
diagnosed with presumed monophasic ADS progressed to 
MS. In the 118 children not progressing to MS or NMOsd, 
97 (82%) children were followed-up for >2 years and 111 
(94%) children were followed-up for >1 year. No children with 
Table 1 Characteristics of all children in the study based on their 
validated diagnoses
ADS Number of 
children
Female, 
n (%)
Age at onset, 
median (range)
ADEMa 50 19 (38) 5.4 (0.8–17.2)
CISa 35 25 (71) 15.9 (3.4–17.9)
ONa 78 54 (69) 16.3 (4.1–18.0)
TMa 20 7 (35) 12.6 (2.5–17.6)
NMOsdb 5 1 (20) 12.2 (2.8–14.8)
MSb 61 44 (72) 16.5 (9.3–18.0)
ADS total 184 116 (58) 14.8 (0.8–18.0)
Children without 
validated ADS diagnosis 225 110 (49) 9.1 (0.0–17.9)
Notes: aDiagnosis at onset. Children with initially presumed monophasic ADS may 
progress to MS or NMOsd during follow-up. bDiagnosis at the end of follow-up 
(June 1, 2016). Children with MS or NMOsd may have initially been diagnosed with 
a monophasic ADS.
Abbreviations: ADEM, acute disseminated encephalomyelitis; ADS, acquired 
demyelinating syndrome; CIS, clinically isolated syndrome; MS, multiple sclerosis; 
NMOsd, neuromyelitis optica spectrum disorder; ON, optic neuritis; TM, transverse 
myelitis.
Table 2 PPVs of a validated ADS diagnosis for ICD-10 codes in the Danish National Patient Register
Diagnosis Children with at least one 
code as either primary 
diagnosis or secondary 
diagnosis (denominator) 
and the specific medical-
record validated ADS 
(numerator)
Children with at least two 
codes as either primary 
diagnosis or secondary 
diagnosis (denominator) 
and the specific medical-
record validated ADS 
(numerator) 
Children with at least 
one code as primary 
diagnosis (denominator) 
and the specific medical-
record validated ADS 
(numerator) 
Children with at least 
one code as either 
primary diagnosis or 
secondary diagnosis 
(denominator) and any 
medical-record validated 
ADS (numerator)
Pd PPV (exact 
95% CI)
Pd PPV (exact 
95% CI)
Pd PPV (exact 
95% CI)
Pd PPV (exact 
95% CI)
ADEM 29/197 0.15 (0.10–0.20) 15/55 0.27 (0.16–0.41) 25/148 0.17 (0.11–0.24) 41/197 0.20 (0.15–0.27)
CISa 31/117 0.27 (0.19–0.35) 7/35 0.20 (0.8–0.37) 29/103 0.28 (0.20–0.38) 76/117 0.65 (0.56–0.74)
ON 77/108 0.71 (0.62–0.80) 29/33 0.88 (0.72–0.97) 58/81 0.72 (0.61–0.81) 79/108 0.73 (0.64–0.81)
TM 16/25 0.64 (0.43–0.82) 9/10 0.90 (0.56–1.00) 14/22 0.64 (0.41–0.83) 22/25 0.88 (0.69–0.97)
NMOsdb 3/7 0.43 (0.10–0.82) 2/2 1.00 (0.16–1.00) 2/4 0.50 (0.07–0.93) 5/7 0.71 (0.29–0.96)
MSc 55/59 0.93 (0.84–0.98) 23/25 0.92 (0.74–0.99) 48/51 0.94 (0.84–0.99) 59/59 1.00 (0.93–1.00)
All children – – – 184/409 0.45 (0.40–0.50)
Notes: aDiagnosis at onset. bDiagnosis at the end of follow-up. cIn the studied cohort, 59 children (in addition to non-MS diagnostic codes) were registered with a diagnostic 
code of MS (G35), of whom 55 truly had MS. The capture of MS was presumably incomplete for MS in Denmark during the same period. dThe sum of the column numerators 
may exceed 184 because children can have both a monophasic ADS at onset and replasing disease at follow-up end. The sum of the column denominators may exceed 409 
because children may be registered with more than one ADS code.
Abbreviations: ADEM, acute disseminated encephalomyelitis; ADS, acquired demyelinating syndrome; CI, confidence interval; CIS, clinically isolated syndrome; ICD-10, 
International Classification of Diseases revision 10; MS, multiple sclerosis; NMOsd, neuromyelitis optica spectrum disorder; ON, optic neuritis; P, proportion; PPV, positive 
predictive value; TM, transverse myelitis.
diagnosis was 0.71 (95% CI =0.62–0.80) for ON, 0.64 (95% 
CI =0.43–0.82) for TM, and 0.93 (95% CI =0.84–0.98) 
for MS (Table 2). The PPV was lower for CIS and ADEM 
(<0.44), and due to few children with NMOsd, CIs were wide 
(PPV =0.43; 95% CI =0.10–0.82). By restricting the analysis 
to having two or more diagnostic codes as either primary 
discharge diagnosis or secondary discharge diagnosis of the 
specific ADS, the PPV increased for ADEM, ON, TM, and 
NMOsd but considerably reduced the number of studied 
children. Interestingly, the inclusion of only primary diagno-
ses did not increase PPVs but only decreased the number of 
studied patients. When using any ADS as outcome (instead 
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ADEM progressed to MS, NMOsd or  multiphasic ADEM. 
A high risk for MS was seen in children initially diagnosed 
with ON (38%) and CIS (83%), but the MS risk was low 
in children with TM (5%). In contrast, the highest risk for 
NMOsd was in children initially diagnosed with TM (15%), 
whereas the risk of NMOsd was only 3% in children with ON.
Other common outcome measures
Assuming a complete coverage of pediatric non-MS ADS in 
Denmark during the study period, the incidence of ON was 
0.81/100,000 per year in children younger than 18 years and 
that of TM was 0.21/100,000, but that of NMOsd was only 
0.05/100,000. The sensitivity was high for ON (0.99; 95% CI 
=0.93–1.00) and TM (0.80; 95% CI =0.56–0.94) but lower for 
ADEM (0.58; 95% CI =0.43–0.72). For NMOsd (0.60; 95% 
CI =0.15–0.95) and CIS (DIS) (0.83; 95% CI =0.36–1.00) the 
sensitivity CIs were too wide to make conclusions (Table 4). 
Due to the low prevalence of pediatric ADS, the PPVs were 
lower than the sensitivities. Specificities and negative predic-
tive values were 1.00 for all non-MS ADS.
Discussion
Based on 415 children registered with at least one diagnostic 
ADS code in the NPR during 2008–2015 and using chart 
review as the gold standard for true diagnoses, we found an 
excellent PPV for MS (0.93; 95% CI =0.84–0.98) and accept-
able PPV for ON (0.71; 95% CI =0.62–0.80) and TM (0.64; 
95% CI =0.43–0.82) but poor PPV for CIS (0.27; 95% CI 
=0.19–0.35) and ADEM (0.15; 95% CI =0.10–0.20); NMOsd 
was inconclusive. Due to the low prevalence of pediatric 
ADS, the sensitivity was excellent for ON (0.99; 95% CI 
=0.93–1.00) and fair for TM (0.80; 95% CI =0.56–0.94) but 
poor for ADEM (0.58; 95% CI =0.43–0.72). During the mean 
follow-up of 4.6 years, 33% of children initially diagnosed 
with presumed monophasic ADS progressed to MS.
The strengths of our study are that it is population based 
and grounded in prospectively collected data from a nation-
wide administrative register with high completeness. In addi-
tion, all medical records (n=415) including follow-up case 
notes were reviewed by experienced pediatric neurologists. 
However, some limitations must be mentioned. The authors 
Table 3 Risk of developing MS or NMOsd during follow-up among children with an initial medical-record verified diagnosis of ADS
Diagnoses Follow-up (years), 
mean ± SD 
(range)
Children initially diagnosed with monophasic ADS (denominator) 
who developed MS or NMOsd during follow-up (numerator)
MS NMOsd
n Proportion (95% CI) n Proportion (95% CI)
ADEM 4.6±2.3 (0.8–8.3) 0/50 0 (0.00–0.07) 0/50 0 (0.00–0.07)
CIS 5.1±2.2 (0.5–9.4) 29/35 0.83 (0.66–0.93) 0/35 0 (0.00–0.10)
ON 4.5±2.3 (0.5–8.3) 30/78 0.38 (0.28–0.50) 2a/78 0.03 (0.003–0.09)
TM 4.3±2.2 (0.3–7.9) 1/20 0.05 (0.001–0.25) 3b/20 0.15 (0.03–0.38)
All ADS 4.6±2.3 (0.3–9.4) 61/184 0.33 (0.26–0.40) 5/184 0.03 (0.009–0.06)
Notes: aOne child had ON and positive AQ4, and one child had ON and then TM but negative AQ4. bThree children had TM and positive AQ4.
Abbreviations: AQ4, aquaporin-4 antibody; ADEM, acute disseminated encephalomyelitis; ADS, acquired demyelinating syndrome; CI, confidence interval; CIS, clinically 
isolated syndrome; MS, multiple sclerosis; NMOsd, neuromyelitis optica spectrum disorder; ON, optic neuritis; SD, standard deviation; TM, transverse myelitis.
Table 4 Incidence rate, prevalence, sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood 
ratios for each non-MS ADS group
Outcome measure ADEMc CIS (DIS)d NMOsdd ONc TMc
Incidence ratea 0.52 0.06 0.05 0.81 0.21
Point prevalenceb 9.35 0.72 0.70 2.93 1.76
Sensitivity (95% CI) 0.58 (0.43–0.72) 0.83 (0.36–1.00) 0.60 (0.15–0.95) 0.99 (0.93–1.00) 0.80 (0.56–0.94)
Specificity (95% CI) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
Positive predictive value (95% CI) 0.15 (0.10–0.20) 0.04 (0.05–0.17) 0.43 (0.10–0.82) 0.71 (0.62–0.80) 0.64 (0.43–0.82)
Negative predictive value (95% CI) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
Positive likelihood ratio 4,132 5,937 179,533 38,112 106,389
Negative likelihood ratio 0.42 0.17 0.40 0.01 0.20
Notes: aNew cases of chart-verified ADS per 100,000 person-years in children younger than 18 years. bThe point prevalence in children (<18 years) was calculated as the 
sum of the age-specific incidence rates times the remaining years up to 18 years of age. cDiagnosis at onset. dDiagnosis at the end of follow-up.
Abbreviations: ADEM, acute disseminated encephalomyelitis; ADS, acquired demyelinating syndrome; CI, confidence interval; CIS (DIS), clinically isolated syndrome 
including dissemination in space but not dissemination in time; MS, multiple sclerosis; NMOsd, neuromyelitis optica spectrum disorder; ON, optic neuritis; TM, transverse 
myelitis.
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were not blinded to the children’s ICD-10 codes during chart 
review. Furthermore, the MS cohort was not complete for 
the time period, and we were not able to have a secondary 
review of MRIs in the ADS cohort. The study design was 
retrospective, and consequently, more children with presumed 
monophasic ADS could have NMOsd with more systematical 
diagnostic workup. Finally, more children with monophasic 
ADS may progress to MS or NMOsd with longer follow-up.
Owing to the risk of developing a chronic demyelinating 
disease, children with non-MS ADS are referred to hospitals 
as either admissions or outpatient ambulatory consultations, 
with subsequent ICD-10 code notification to the NPR. For 
our cohort, only ICD-10 codes were used during the study 
period. We presume high completeness for ICD-10 codes 
because hospitals are reimbursed based on their reporting 
of ICD-10 codes in the Danish health care system, which 
is tax funded. Private consultant neurologists, pediatricians, 
or ophthalmologists always refer children to hospitals when 
suspecting demyelinating CNS disease; accordingly, it is 
unlikely that children with non-MS ADS are not registered 
with one of the aforementioned diagnostic codes. Our study 
for non-MS ADS is therefore nationwide and population 
based. Moreover, we accessed the medical records in all 
children who were registered with the ICD-10 codes during 
the study period. Furthermore, diagnostic criteria for ADS 
were relatively uniform for the study period.
We have previously estimated the annual incidence of 
pediatric MS as 0.88 (95% CI =0.71–1.09) per 100,000 
person-years in children before the age of 18 years during 
2008–2015, using the same data as for the current study but 
with additional information on incident MS cases from the 
Danish Multiple Sclerosis Registry.27–29 Therefore, our cover-
age of MS is ~70%. However, due to the natural reporting 
delay in MS, we may have underestimated the incidence of 
the disease because patients in our study period with their 
first neurological symptom may progress to MS with longer 
follow-up time.14,15 In addition, AQ4 is not routinely investi-
gated in all children with TM or ON and some misclassifica-
tion of children truly having NMOsd may have been present 
with more thorough diagnostic workup. Lack of uniformly 
accepted diagnostic criteria for ADEM may also complicate 
comparison with other studies because diagnostic criteria for 
true ADEM may differ. Follow-up of our cohort will presum-
ably increase the proportion of children with monophasic 
ADS who progress to relapsing disease and thereby reduce 
this misclassification.
The PPV of ADEM (the commonest ADS in children) 
was low; therefore, we explored algorithms to improve PPV 
compared with the remaining children with non-ADEM ADS, 
but as the PPV increased, the false positive rate increased con-
siderably. One cause could be the lack of uniformly accepted 
diagnostic criteria for ADEM in Danish clinical practice.22 
Furthermore, the physician giving the child an ICD-10 diag-
nostic code at discharge may be a general pediatrician not 
specialized in neurology. This may also be complicated by the 
existence of many ICD-10 codes for demyelinating diseases 
(illustrated by the prespecified diagnostic ICD-10 codes for 
ADEM) and lack of coding guidelines. The same applies to 
hemispheric demyelinating lesions causing hemisensory or 
motor deficits that physicians assume represent onset of MS 
(our CIS group).
We suggest that future ICD revisions create one category 
only for persons with brainstem or hemispheric syndrome of 
CIS and one for ADEM instead of multiple unspecific cat-
egories of acute demyelination. This should be accompanied 
by ICD coding guidelines for ADS to improve consistency 
in terminology. In addition, isolated ON or TM without 
cerebral demyelinating lesions should be coded differently 
from ON or TM with cerebral demyelinating lesions (CIS) 
due to the higher risk of disease progression to MS in the 
latter. Future research should focus on diagnostic ICD-10 
coding of NMOsd in cohorts of children with ON and TM 
whose diagnostic workup includes the evaluation of AQ4 and 
MOG in all children.
Conclusion
PPV was high for MS and acceptable for ON and TM; 
these ICD-10 codes are therefore useful for epidemiologi-
cal studies. In contrast, PPV was low for CIS and ADEM; 
NMOsd was inconclusive. Progression from monophasic 
ADS to MS/NMOsd, continual revisions and relaxation of 
diagnostic criteria of MS and NMOsd, varying diagnostic 
criteria for ADEM, and lack of ICD coding guidelines for 
ADS may decrease the validity of ADS diagnoses in the 
NPR.
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Supplementary materials
Table S1 ICD-10 diagnostic groups, codes, and their description
Diagnostic groups ICD-10 codes Description
Multiple sclerosis G35 Multiple sclerosis
Neuromyelitis optica spectrum disorders G36.0 Neuromyelitis optica (Devic)
Acute disseminated encephalomyelitis G04.0 Acute disseminated encephalitis
G04.8 Other encephalitis, myelitis, and encephalomyelitis
G04.9 Encephalitis, myelitis, and encephalomyelitis, unspecified
Transverse myelitis G37.3 Acute transverse myelitis in demyelinating disease of the central nervous system
Optic neuritis H46 Optic neuritis
Clinically isolated syndrome G36.8 Other specified acute disseminated demyelination
G36.9 Acute disseminated demyelination, unspecified
G37.8 Other specified demyelinating diseases of the central nervous system
G37.9 Demyelinating disease of the central nervous system, unspecified
Abbreviation: ICD-10, International Classification of Diseases revision 10.
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